New web tool aims to clear up breast cancer risk confusion
NCT ID NCT05810025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested a web-based decision aid called RealRisks in 70 high-risk women aged 35-74. The tool combines electronic health records and patient-reported data to calculate breast cancer risk and improve understanding of prevention options. Researchers measured whether the tool helped women accurately perceive their risk and become more engaged in their health decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RealRisks web-based decision aid
- What this could lead to
- If successful, this approach could help high-risk women better understand their breast cancer risk and make informed prevention choices.
- What could go wrong
- This is a small, completed study with 70 participants, so results may not apply to all groups. The tool is behavioral, not a treatment, so it cannot prevent or cure cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 74 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women, age 35-74 years * High-risk defined as 5-year invasive breast cancer risk ≥1.7% or 10 risk ≥20% according to the BCSC or GAIL models * English- or Spanish-speaking * Able to sign informed consent. Exclusion Criteria: * Women with a personal history of breast cancer * Women who previously participated in a sub-study (Aim 1) of the awarded grant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?